GlobeNewswire Inc | Sep 1, 2021 04:05PM EDT

September 01, 2021

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government andmilitary use, today announced that on August 31, 2021, the Company granted restricted stock units to one new employee of the Company. The award was granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

The restricted stock units are to acquire, in the aggregate, 9,900 shares of the Companys common stock and shall vest upon the conclusion of a 36-monthvesting period, under which one hundred percent 100% of the restricted stock units will vest after 36 months of employment, subject to the employees continuous service. The restricted stock units are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the restricted stock unit award agreement covering the grant.

About Paratek Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc.is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use.

The company's lead commercial product, NUZYRA(omadacycline), isa once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.

Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.

Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA(sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, toAlmirall, LLC(Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

In 2019, Paratek was awarded a contract from BARDA, valued at ~$285 million,to support the development and U.S.-based manufacturing of NUZYRA for the treatment of pulmonary anthrax.

For more information, visitwww.ParatekPharma.comor follow @ParatekPharmaon Twitter.

About NUZYRANUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.

Please see full Prescribing Information for NUZYRA atwww.NUZYRA.com.

CONTACT

For Investors:Hans VitzthumLifeSci Advisorsir@ParatekPharma.comPhone: 617-430-7578

For Media:Beth Kramli Scient PRBeth@scientpr.comPhone: 908-568-9721